Briefing: Opinion: Semaglutide is going off-patent in India. But will people who need it be able to get it?
Strategic angle: Rules determining who gets access to semaglutide in India were written for different bodies with different cardiovascular risks.
The off-patent status of semaglutide in India raises significant questions regarding access for patients. Current regulations were established with specific cardiovascular risk profiles in mind, potentially excluding those who may benefit from the medication.
The implications of these rules are critical for healthcare infrastructure, as they may limit the distribution of semaglutide to a narrow segment of the population. This could lead to disparities in treatment access, particularly among those with varying health conditions.
A reevaluation of access criteria is necessary to ensure that semaglutide reaches all individuals who require it, regardless of their cardiovascular risk. This will require collaboration between healthcare providers and policymakers to adapt existing frameworks.